Immune Boost Treatment After CAR-T or TCE Therapy
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy, Infections clinical trials.
This study tests a new immunoglobulin (antibody) treatment called IgPro20 in adults whose immune systems became weakened after receiving CAR-T cell or TCE therapies for blood cancers. The goal is to help strengthen your immune system and reduce infection risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Diagnosed with a B-cell blood cancer (myeloma, chronic lymphocytic leukemia, non-Hodgkin lymphoma, or B-cell acute lymphoblastic leukemia)
- Had CAR-T cell therapy at least 2 months ago OR started TCE therapy at least 1 month ago and plan to continue it
- Your cancer responded well to the CAR-T or TCE treatment (partial or complete response)
- Low immunoglobulin G (IgG) levels, or already receiving immunoglobulin replacement therapy
- No active infection, history of blood clots in last 6 months, or certain other immune conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether IVIG (a blood product that helps fight infections) can lower infection risk after you receive CD19 CAR-T therapy. It’s meant to help protect you during the vulnerable period after CAR-T treatment.
This study tests whether extra geriatric support before and after CAR-T cell therapy helps people 60 and older recover faster. It is for patients with B-cell non-Hodgkin lymphoma or multiple myeloma who are scheduled for an FDA-approved CAR-T treatment.
This study tests whether a weekly infusion of a blood product called IgPro20 can help prevent infections in people with multiple myeloma who are already being treated with a bispecific antibody. If you qualify, you will receive the study treatment and be monitored for safety and infection rates.
This trial checks if giving vaccines after CAR-T cell therapy can help your immune system fight off preventable diseases. It is for adults with certain blood cancers who are about to get CAR-T treatment.
This study tests a new type of CAR-T cell therapy designed to treat certain blood cancers (like leukemia, lymphoma, or multiple myeloma) that have come back or not responded to standard treatment. The cells are enhanced with IL-15 to help them work better.
This study tests a new type of cell therapy called CAR-T cells that target three proteins (CD19, CD22, BCMA) to treat people with autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity.
Hear when a new Secondary Immune Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.